Phase I and II clinical trials of trastuzumab

Annals of Oncology

Volumn 12, Issue SUPPL. 1, 2001, Pages

  Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cisplatin; Clinical trial; Herceptin; Metastatic breast cancer; Pharmacokinetics; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; CISPLATIN; DOXORUBICIN; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; BACTEREMIA; BODY WEIGHT; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; METASTASIS; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; UNITED STATES;

EID: 0034864020     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/12.suppl_1.S49     Document Type: Article

References (55)

1. The product of the c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
2. The neu oncogene encodes an epidermal growth factor receptor-related protein
3. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
4. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32
5. Basic science of HER-2/neu: A review
6. The biology of erbB-2/neu/HER-2 and its role in cancer
7. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation
8. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen
9. EGF-related peptides and their receptors in mammary gland development
10. EGF-related peptides in the pathophysiology of the mammary gland
11. Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer
12. Dynamic expression and activation of ErbB receptors in the developing mouse mammary gland
13. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms
14. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
15. Regulation of signal transduction and signal diversity by receptor oligomerization
16. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
17. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling
18. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
19. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
20. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
21. 3 cells
22. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
23. HER2 causes transformation and tumorigenesis of NIH3T3 cell
24. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
25. HER2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
26. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
27. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
28. Studies of the HER-2neu proto-oncogene in human breast and ovarian cancer
29. Should HER2 status be routinely measured for all breast cancer patients?
30. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
31. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen
32. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
33. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines
34. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
35. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185
36. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor functions and inhibits tumor cell growth
37. HER2 signal transduction in breast cancer cells
38. Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB2 receptor on tumor growth
39. Differential responses of human tumor cell lines to anti-HER2 monoclonal antibodies
40. HER2 antibody for human cancer therapy
41. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
42. Recombinant humanized anti-HER2 antibody (Herceptin®) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
43. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
44. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
45. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product
46. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
47. Tolerability in patients receiving trastuzumab with or without chemotherapy
48. Ongoing trials with trastuzumab in metastatic breast cancer
49. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
50. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
51. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory chemotherapy treatment
52. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
53. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
54. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
55. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin)